AMAZE™ Asthma Implementation QI Study

AstraZeneca

Status: Completed

Conditions: Asthma

Treatments: Device: AMAZE™ Disease Management Platform

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT04901260

N3566000000

Details and patient eligibility

About

The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Full description

AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of patients throughout their patient care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.

Enrollment: 117 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >18 years of age at the time of enrollment
• Clinically confirmed diagnosis of asthma
• Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
• Able to understand and speak English sufficiently to be able to use the AMAZE™ patient App
• Willingness to participate in a telephone interview and be audio-recorded
• Consenting to participate in the study

Exclusion criteria

• Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma;
• Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™

Trial design

117 participants in 1 patient group

Quality Initiative

Description:

Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and GAA clinical staff.

Treatment:

Device: AMAZE™ Disease Management Platform